![dreamstime page 10B m 24640718](https://drcatalona.com/wp-content/uploads/2024/04/dreamstime-page-10B_m_24640718-300x300.jpeg)
[225] Actinium-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
This retrospective, international study examined the safety and antitumor activity in 488 patients who had received previous treatment including docetaxel, cabazitaxel, abiraterone, and enzalutamide, lutetium-177 PSMA, and radium-223 dichloride. A decline in PSA was noted in 73% of patients, with…